Thyroxine (T4)+triiodothyronine (T3) combination therapy can be considered in case of persistent symptoms despite normal serum thyroid stimulating hormone in levothyroxine (LT4)-treated hypothyroid patients. Combination therapy has gained popularity in the last two decades, especially in countries with a relatively high gross domestic product. The prevalence of persistent symptoms has also increased; most frequent are complaints about energy levels and fatigue (80% to 90%), weight management (70% to 75%), memory (60% to 80%), and mood (40% to 50%). Pathophysiological explanations for persistent problems are unrealistic patient expectations, comorbidities, somatic symptoms, related disorders (Diagnostic and Statistical Manual of Mental Disorders [DSM-5]), autoimmune neuroinflammation, and low tissue T3. There is fair circumstantial evidence for the latter cause (tissue and specifically brain T3 content is normalized by T4+T3, not by T4 alone), but the other causes are viewed as more relevant in current practice. This might be related to the ‘hype’ that has emerged surrounding T4+T3 therapy. Although more and better-designed trials are needed to validate the efficacy of T4+T3 combination, the management of persistent symptoms should also be directed towards alternative causes. Improving the doctor-patient relationship and including more and better information is crucial. For example, dissatisfaction with the outcomes of T4 treatment for subclinical hypothyroidism can be anticipated as recent trials have demonstrated that LT4 is hardly effective in improving symptoms associated with subclinical hypothyroidism.
Citations
Citations to this article as recorded by
Association of DIO2 and MCT10 Polymorphisms With Persistent Symptoms in LT4-Treated Patients in the UK Biobank Christian Zinck Jensen, Jonas Lynggaard Isaksen, Gustav Ahlberg, Morten Salling Olesen, Birte Nygaard, Christina Ellervik, Jørgen Kim Kanters The Journal of Clinical Endocrinology & Metabolism.2024; 109(2): e613. CrossRef
Quality of life, daily functioning, and symptoms in hypothyroid patients on thyroid replacement therapy: A Dutch survey Ellen Molewijk, Eric Fliers, Koen Dreijerink, Ad van Dooren, Rob Heerdink Journal of Clinical & Translational Endocrinology.2024; 35: 100330. CrossRef
Use of thyroid hormones in hypothyroid and euthyroid patients: A survey of members of the Endocrine Society of Australia Nicole Lafontaine, Suzanne J. Brown, Petros Perros, Enrico Papini, Endre V. Nagy, Roberto Attanasio, Laszlo Hegedüs, John P. Walsh Clinical Endocrinology.2024; 100(5): 477. CrossRef
Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients: A THESIS questionnaire survey of members of the Irish Endocrine Society Mohamad Mustafa, Elsheikh Ali, Anne McGowan, Laura McCabe, Laszlo Hegedüs, Roberto Attanasio, Endre V. Nagy, Enrico Papini, Petros Perros, Carla Moran Irish Journal of Medical Science (1971 -).2023; 192(5): 2179. CrossRef
Re: “Exploring the Genetic Link Between Thyroid Dysfunction and Common Psychiatric Disorders: A Specific Hormonal or a General Autoimmune Comorbidity” by Soheili-Nezhad et al. Christiaan F. Mooij, A.S. Paul van Trotsenburg Thyroid®.2023; 33(8): 999. CrossRef
Circulating thyroid hormones and clinical parameters of heart failure in men Iva Turić, Ivan Velat, Željko Bušić, Viktor Čulić Scientific Reports.2023;[Epub] CrossRef
Evaluation of cortical and trabecular bone structure of the mandible in patients using L-Thyroxine Melike Gulec, Melek Tassoker, Mediha Erturk BMC Oral Health.2023;[Epub] CrossRef
The Impact of Hypothyroidism on Satisfaction with Care and Treatment and Everyday Living: Results from E-Mode Patient Self-Assessment of Thyroid Therapy, a Cross-Sectional, International Online Patient Survey Petros Perros, Laszlo Hegedüs, Endre Vezekenyi Nagy, Enrico Papini, Harriet Alexandra Hay, Juan Abad-Madroñero, Amy Johanna Tallett, Megan Bilas, Peter Lakwijk, Alan J. Poots Thyroid.2022;[Epub] CrossRef